• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22857 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal use guide: antibiotic prophylaxis during clean orthopedic surgery in children and adults]
2017     Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal usage guide: cellulitis in adults and children]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal long-term use of proton pump inhibitors]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Optimal blood transfusion management in elective orthopaedic surgery]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Optical coherence tomography: usefulness in glaucoma, diabetic retinopathy and age-related macular degeneration]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Optical coherence tomography angiography in vascular eye diseases]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Optical coherence tomography (OCT) for neovascular age-related macular degeneration as well as diabetic retinopathy with macular oedema]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Opportunities and strategies to drive appropriate use of MRI in Austria. Part 2]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Opicapone (Parkinson disease): Addendum to Commission A16-61]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Opicapone (Parkinson disease) - Benefit assessment according to §35a Social Code Book V]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Ophthalmic implants in glaucoma surgery. Safety and effectiveness analysis]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Operation for vaginal prolapse in day surgery - a health technology assessment]
2022     Norwegian Institute of Public Health (NIPH) [Operating room ventilation: a health technology assessment]
2008     The Swedish Council on Health Technology Assessment (SBU) [Open angle glaucoma - diagnosis, follow-up, and treatment]
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) [Onnikka® lifestyle intervention application for weight management]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Online hemodiafiltration: evaluation of its safety, effectiveness, cost and usage indications]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [OncotypeDX in breast cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Onasemnogene abeparvovec (Zolgensma®) for spinal muscular atrophy]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Onasemnogene abeparvovec (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Onasemnogene abeparvovec (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V - Addendum]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Onasemnogene abeparvovec (spinal muscular atrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ombitasvir/paritaprevir/ritonavir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Ombitasvir, paritaprevir and ritonavir regimens in hepatitis C patients]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Omalizumab for the management of asthma]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olopatadine/mometasone furoate (allergic rhinitis) - Addendum to Commission A22-125]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olopatadine/mometasone (allergic rhinitis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olipudase alfa (ASMD) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaratumab (sarcoma) - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Olaparib in ovarian cancer]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) – Second Addendum to Commission A23-03]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) – Addendum to Commission A23-03]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) - Benefit assessment according to § 35a SGB V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) - Addendum to Commission A20-106]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian, fallopian tube, peritoneal cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Addendum to Commission A20-111]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (breast cancer) - Addendum to Commission A19-57]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (breast cancer, adjuvant) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (breast cancer, adjuvant) - Addendum to Commission A22-89]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (adenocarcinoma of the pancreas) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2008     Committee for New Health Technology Assessment (CNHTA) [Office-based laryngeal surgery with 585-nm pulsed dye laser and local anesthesia]
2021     Norwegian Institute of Public Health (NIPH) [Ofatumumab for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment – health economic evaluation]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Odronextamab (follicular lymphoma in adults); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Odronextamab (diffuse large B-cell lymphoma in adults); assessment according to §35a Social Code Book V; search for disease registries]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Odevixibat (cholestasis [from 6 months]) - Assessment according to § 35a (1), Sentence 11, Social Code Book V]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Ocular biometry of the anterior chamber depth using IOL Master® and Pentacam®]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ocriplasmin (vitreomacular traction) - Addendum to Commission A18-68]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ocriplasmin (vitreomacular traction, including when associated with macular hole) - Benefit assessment according to §35a Social Code Book V (reassessment after expiry of the decision)]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ocriplasmin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ocrelizumab (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ocrelizumab (multiple sclerosis) - Addendum to Commission A18-06]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Occupational therapy. Part I: status quo in Austria and part II: occupational therapy for rheumatoid arthritis]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Occupational therapy part III. Occupational therapy for patients after stroke]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Occupational therapy in children; Part 1 – Literature review on indications, utilisation and recommendations]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Occupational therapy for dementia and depression]
2017     The Swedish Council on Health Technology Assessment (SBU) [Occupational health and safety – chemical exposure]
2014     The Swedish Council on Health Technology Assessment (SBU) [Occupational exposures and symptoms of depression and burnout]
2013     The Swedish Council on Health Technology Assessment (SBU) [Occupational exposures and sleep disturbances]
2016     The Swedish Council on Health Technology Assessment (SBU) [Occupational exposures and osteoarthritis]
2012     The Swedish Council on Health Technology Assessment (SBU) [Occupational exposures and neck and upper extremity disorders]
2014     The Swedish Council on Health Technology Assessment (SBU) [Occupational Exposures and Back Disorders]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Occupational exposures and asthma and COPD]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Occupational exposure and upper extremity pain]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Occupational chemical exposures and cardiovascular disease]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Observation of technologies after their introduction into clinical practice. Prioritisation and assessment protocol proposal]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Objectively derived approach for the development of search strategies in bibliographic databases]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (non-pretreated advanced follicular lymphoma) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (follicular lymphoma, first line) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (follicular lymphoma, after rituximab) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinituzumab - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obeticholic acid (primary biliary cholangitis) - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Nutritional treatment of patients with chronic obstructive pulmonary disease in a state of malnutrition]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Nutritional treatment of multi-morbid patients in a state of malnutrition]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Nutritional therapy in heart failure patients with malnutrition]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Nutritional counseling in general practice by doctor or dietician]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Nutritional care of medical patients - a health technology assessment]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Nusinersen in spinal muscular atrophy]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Nusinersen (Spinraza®) in spinal muscular atrophy]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nusinersen (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nusinersen (spinal muscular atrophy) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nusinersen (spinal muscular atrophy) - Addendum to Commission A20-114]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Nurse-endoscopy of the colon; a randomized trial on accuracy, patient experiences and costs]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Number of tonsillitis episodes: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Nucleoplasty for treating disk herniation]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Nucleoplasty for patients with discogenic back pain]
2016     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Nucleolysis percutaneous laser disc decompression]
2009     Committee for New Health Technology Assessment (CNHTA) [NTRK1 gene point mutation analysis]
2008     Committee for New Health Technology Assessment (CNHTA) [NR0B1 gene, mutation[sequencing]]
2009     Committee for New Health Technology Assessment (CNHTA) [NPM1 mutant mRNA, quantitative [real-time RT-PCR]]
2009     Committee for New Health Technology Assessment (CNHTA) [NPM1 gene sequencing analysis]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [NovoSeven for massive, uncontrollable, life-threatening haemorrhage in non-haemophiliacs]